Biocardia Inc (BCDA)

$1.08 -0.02 (-1.82%)
Market Cap 16.35M
Revenue (ttm) 0.00
Net Income (ttm) -8.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 137,000
Avg Vol 276,496
Day's Range N/A - N/A
Shares Out 15.14M
Stochastic %K 18%
Beta 0.55
Analysts Sell
Price Target $15.50

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 226 0120
Fax: 650 631 3731
Address:
320 Soquel Way, Sunnyvale, United States
rrey21
rrey21 Sep. 14 at 3:35 PM
$BCDA Can't wait for it to be over$30 per share!
0 · Reply
winteemelon123
winteemelon123 Sep. 12 at 4:59 AM
$BCDA BioCardia probably the most advanced in study. I think FDA would expedite its review upon pma submission.
1 · Reply
winteemelon123
winteemelon123 Sep. 12 at 4:58 AM
$BCDA A significant advantage over Reheart is CardiAMP does not need invasive open heart surgery as protocol. Many of the targetted patient population probably would be wise to avoud open heart surgery if possible.
0 · Reply
winteemelon123
winteemelon123 Sep. 11 at 10:08 PM
$BCDA
0 · Reply
winteemelon123
winteemelon123 Sep. 11 at 9:14 PM
$BCDA multi billion dollars in market potential with initial commercialisation expected next year upon expected approvals yet little buying and selling.
0 · Reply
winteemelon123
winteemelon123 Sep. 11 at 8:03 AM
$BCDA
0 · Reply
winteemelon123
winteemelon123 Sep. 11 at 7:02 AM
$BCDA imo they could file for PMA next year and need not wait for study completion.
0 · Reply
winteemelon123
winteemelon123 Sep. 11 at 7:01 AM
$BCDA Helix is a pipeline in a product.
1 · Reply
Whateverbro
Whateverbro Sep. 10 at 10:16 PM
$BCDA they filed an 8-k today. about the event in New York. also they still on time for Q3 PREsubmison for the Helix follow-on-de-Nova pre-submission.
1 · Reply
Wizee13
Wizee13 Sep. 10 at 4:39 PM
$BCDA I love how people are talking about fundamentals here, not just chart :)
0 · Reply
Latest News on BCDA
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

Sep 10, 2026, 8:30 AM EDT - 4 days ago

BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

BioCardia gets FDA confirmation of Helix meeting minutes

2026-08-24T13:00:34.000Z - 21 days ago

BioCardia gets FDA confirmation of Helix meeting minutes

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

Aug 24, 2026, 8:30 AM EDT - 21 days ago

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

BioCardia Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 4 weeks ago

BioCardia Earnings Call Transcript: Q2 2026

BioCardia Quarterly report: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 4 weeks ago

BioCardia Quarterly report: Q2 2026

BioCardia Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 4 weeks ago

BioCardia Earnings release: Q2 2026

BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026

Aug 5, 2026, 3:16 PM EDT - 5 weeks ago

BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026

BioCardia issues letter to shareholders on 2026 priorities

2026-06-18T13:24:57.000Z - 2 months ago

BioCardia issues letter to shareholders on 2026 priorities

BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities

Jun 18, 2026, 8:00 AM EDT - 2 months ago

BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities

BioCardia Announces $4.4 Million Financing

Jun 8, 2026, 8:00 AM EDT - 3 months ago

BioCardia Announces $4.4 Million Financing

FDA confirms CardiAMP Heart Failure II Trial may support premarket approval

2026-06-05T12:10:44.000Z - 3 months ago

FDA confirms CardiAMP Heart Failure II Trial may support premarket approval

FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF

Jun 5, 2026, 8:00 AM EDT - 3 months ago

FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency

May 21, 2026, 8:00 AM EDT - 3 months ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency

BioCardia Transcript: A.G.P.'s Annual Virtual Healthcare Conference

May 20, 2026, 11:40 AM EDT - 3 months ago

BioCardia Transcript: A.G.P.'s Annual Virtual Healthcare Conference

BioCardia Earnings Call Transcript: Q1 2026

May 15, 2026, 4:30 PM EDT - 4 months ago

BioCardia Earnings Call Transcript: Q1 2026

BioCardia Earnings release: Q1 2026

May 15, 2026, 4:30 PM EDT - 4 months ago

BioCardia Earnings release: Q1 2026

BioCardia Quarterly report: Q1 2026

May 15, 2026, 4:30 PM EDT - 4 months ago

BioCardia Quarterly report: Q1 2026

BioCardia Reports First Quarter 2026 Business Highlights and Financial Results

May 15, 2026, 8:00 AM EDT - 4 months ago

BioCardia Reports First Quarter 2026 Business Highlights and Financial Results

BioCardia Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 4 months ago

BioCardia Slides: Corporate presentation

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026

May 11, 2026, 5:10 PM EDT - 4 months ago

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026

BioCardia provides update on Helix pre-submission meeting with FDA

2026-05-08T18:14:28.000Z - 4 months ago

BioCardia provides update on Helix pre-submission meeting with FDA

BioCardia Slides: Corporate presentation

Apr 28, 2026, 7:00 AM EDT - 4 months ago

BioCardia Slides: Corporate presentation

BioCardia reports ‘positive’ outcome in consult with Japan’s PMDA for CardiAMP

2026-04-20T13:09:35.000Z - 4 months ago

BioCardia reports ‘positive’ outcome in consult with Japan’s PMDA for CardiAMP

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

Apr 20, 2026, 8:00 AM EDT - 4 months ago

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

BioCardia files request for meeting with FDA to discuss CardiAMP pathway

2026-04-02T14:20:13.000Z - 5 months ago

BioCardia files request for meeting with FDA to discuss CardiAMP pathway

BioCardia Earnings Call Transcript: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

BioCardia Earnings Call Transcript: Q4 2025

BioCardia Earnings release: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

BioCardia Earnings release: Q4 2025

BioCardia Annual report: Q4 2025

Mar 24, 2026, 4:30 PM EDT - 5 months ago

BioCardia Annual report: Q4 2025

BioCardia Reports 2025 Business Highlights and Financial Results

Mar 24, 2026, 4:05 PM EDT - 5 months ago

BioCardia Reports 2025 Business Highlights and Financial Results

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

Mar 19, 2026, 7:47 PM EDT - 5 months ago

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

BioCardia’s pre-submission package for Helix catheter approved by FDA

2026-03-17T10:05:13.000Z - 6 months ago

BioCardia’s pre-submission package for Helix catheter approved by FDA

BioCardia reports results from Phase III trial for ischemic heart failure

2026-03-03T13:42:33.000Z - 6 months ago

BioCardia reports results from Phase III trial for ischemic heart failure

BioCardia files pre-submission for FDA approval of Helix catheter

2026-02-10T14:21:02.000Z - 7 months ago

BioCardia files pre-submission for FDA approval of Helix catheter

BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

Feb 10, 2026, 9:15 AM EST - 7 months ago

BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

BioCardia completed third preliminary clinical consultation with Japan’s PMDA

2025-12-16T13:10:48.000Z - 9 months ago

BioCardia completed third preliminary clinical consultation with Japan’s PMDA

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

Dec 16, 2025, 8:00 AM EST - 9 months ago

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

BioCardia appoints Slosman to its Board of Directors

2025-12-03T13:16:10.000Z - 9 months ago

BioCardia appoints Slosman to its Board of Directors

NSPR

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

Dec 1, 2025, 8:30 AM EST - 9 months ago

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

BioCardia appoints Farhan Shahab as VP, quality

2025-11-24T13:41:01.000Z - 9 months ago

BioCardia appoints Farhan Shahab as VP, quality

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

Nov 24, 2025, 8:15 AM EST - 9 months ago

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

Nov 12, 2025, 4:40 PM EST - 10 months ago

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

BioCardia Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

BioCardia Earnings Call Transcript: Q3 2025

BioCardia Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

BioCardia Earnings release: Q3 2025

BioCardia Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

BioCardia Quarterly report: Q3 2025

BioCardia first patient enrolled at Henry Ford Health for Phase 3 CardiAMP

2025-11-10T13:47:11.000Z - 10 months ago

BioCardia first patient enrolled at Henry Ford Health for Phase 3 CardiAMP

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

Nov 5, 2025, 7:29 PM EST - 10 months ago

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

BioCardia Proxy statement: Proxy Filing

Nov 3, 2025, 7:00 AM EST - 10 months ago

BioCardia Proxy statement: Proxy Filing

BioCardia announces patient enrolled at Wisconsin School for CardiAMP trial

2025-10-30T12:26:50.000Z - 10 months ago

BioCardia announces patient enrolled at Wisconsin School for CardiAMP trial

BioCardia regains compliance with Nasdaq listing requirements

2025-10-02T12:10:31.000Z - 11 months ago

BioCardia regains compliance with Nasdaq listing requirements

BioCardia Regains Compliance with Nasdaq Listing Requirements

Oct 2, 2025, 8:00 AM EDT - 11 months ago

BioCardia Regains Compliance with Nasdaq Listing Requirements

BioCardia announces preliminary consultation with Japan PDMA on CardiAMP results

2025-09-22T12:05:28.000Z - 11 months ago

BioCardia announces preliminary consultation with Japan PDMA on CardiAMP results

BioCardia prices 4.8M shares at $1.25 in public offering

2025-09-18T13:25:16.000Z - 12 months ago

BioCardia prices 4.8M shares at $1.25 in public offering

BioCardia Announces Pricing of Up To $12 Million Public Offering

Sep 18, 2025, 9:15 AM EDT - 12 months ago

BioCardia Announces Pricing of Up To $12 Million Public Offering

BioCardia announces CardiAMP Cell Therapy results

2025-09-18T11:07:02.000Z - 12 months ago

BioCardia announces CardiAMP Cell Therapy results

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

Sep 18, 2025, 7:00 AM EDT - 12 months ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

BioCardia Registration statement: Registration Filing

Sep 17, 2025, 8:00 AM EDT - 12 months ago

BioCardia Registration statement: Registration Filing

BioCardia files to sell 2.8M shares of common stock, warrants

2025-09-16T13:10:38.000Z - 12 months ago

BioCardia files to sell 2.8M shares of common stock, warrants

BioCardia Registration statement: Registration Filing

Sep 16, 2025, 8:00 AM EDT - 12 months ago

BioCardia Registration statement: Registration Filing

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

Sep 4, 2025, 9:00 AM EDT - 1 year ago

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

BioCardia Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q2 2025

BioCardia Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

BioCardia Quarterly report: Q2 2025

BioCardia Earnings release: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings release: Q2 2025

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 11, 2025, 9:15 AM EDT - 1 year ago

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Aug 6, 2025, 3:18 PM EDT - 1 year ago

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

Aug 4, 2025, 6:00 AM EDT - 1 year ago

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

BioCardia Registration statement: Registration Filing

Jul 9, 2025, 8:00 AM EDT - 1 year ago

BioCardia Registration statement: Registration Filing

BioCardia Transcript: A.G.P. Virtual Annual Healthcare Company Showcase

May 21, 2025, 3:40 PM EDT - 1 year ago

BioCardia Transcript: A.G.P. Virtual Annual Healthcare Company Showcase

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 21, 2025, 8:30 AM EDT - 1 year ago

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

BioCardia Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q1 2025

BioCardia Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings release: Q1 2025

BioCardia Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioCardia Quarterly report: Q1 2025

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

May 14, 2025, 4:05 PM EDT - 1 year ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

May 9, 2025, 4:28 PM EDT - 1 year ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

BioCardia Registration statement: Registration Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

BioCardia Registration statement: Registration Filing

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Apr 11, 2025, 9:15 AM EDT - 1 year ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

BioCardia Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings Call Transcript: Q4 2024

BioCardia Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

BioCardia Earnings release: Q4 2024

BioCardia Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

BioCardia Annual report: Q4 2024

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Mar 31, 2025, 1:39 PM EDT - 1 year ago

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

BioCardia Reports 2024 Business Highlights and Financial Results

Mar 26, 2025, 4:30 PM EDT - 1 year ago

BioCardia Reports 2024 Business Highlights and Financial Results

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Mar 21, 2025, 8:30 AM EDT - 1 year ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

Mar 10, 2025, 9:15 AM EDT - 1 year ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Feb 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Feb 13, 2025, 8:30 AM EST - 1 year ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

Jan 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Dec 4, 2024, 8:30 AM EST - 1 year ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioCardia Earnings Call Transcript: Q3 2024

BioCardia Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioCardia Earnings release: Q3 2024

BioCardia Quarterly report: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioCardia Quarterly report: Q3 2024

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 18, 2024, 8:30 AM EDT - 1 year ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Sep 9, 2024, 4:05 PM EDT - 2 years ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 29, 2024, 8:30 AM EDT - 2 years ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

BioCardia Registration statement: Registration Filing

Aug 29, 2024, 8:00 AM EDT - 2 years ago

BioCardia Registration statement: Registration Filing

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 21, 2024, 7:00 AM EDT - 2 years ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Aug 13, 2024, 4:30 PM EDT - 2 years ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

BioCardia Earnings Call Transcript: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings Call Transcript: Q2 2024

BioCardia Quarterly report: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

BioCardia Quarterly report: Q2 2024

BioCardia Earnings release: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings release: Q2 2024

BioCardia Registration statement: Registration Filing

Aug 9, 2024, 8:00 AM EDT - 2 years ago

BioCardia Registration statement: Registration Filing

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jul 17, 2024, 7:00 AM EDT - 2 years ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

Jun 7, 2024, 7:00 AM EDT - 2 years ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

BioCardia Announces Reverse Stock Split

May 21, 2024, 5:00 PM EDT - 2 years ago

BioCardia Announces Reverse Stock Split

BioCardia Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings Call Transcript: Q1 2024

BioCardia Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioCardia Quarterly report: Q1 2024

BioCardia Earnings release: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings release: Q1 2024

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 14, 2024, 4:02 PM EDT - 2 years ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

May 1, 2024, 7:00 AM EDT - 2 years ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

BioCardia Transcript: Status Update

Apr 30, 2024, 3:00 PM EDT - 2 years ago

BioCardia Transcript: Status Update

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Apr 25, 2024, 9:00 AM EDT - 2 years ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

BioCardia Proxy statement: Proxy Filing

BioCardia Proxy statement: Proxy Filing

Apr 4, 2024, 8:00 AM EDT - 2 years ago

BioCardia Proxy statement: Proxy Filing

BioCardia Earnings Call Transcript: Q4 2023

Mar 27, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings Call Transcript: Q4 2023

BioCardia Earnings release: Q4 2023

Mar 27, 2024, 4:30 PM EDT - 2 years ago

BioCardia Earnings release: Q4 2023

BioCardia Annual report: Q4 2023

Mar 27, 2024, 4:30 PM EDT - 2 years ago

BioCardia Annual report: Q4 2023

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 27, 2024, 4:00 PM EDT - 2 years ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

rrey21
rrey21 Sep. 14 at 3:35 PM
$BCDA Can't wait for it to be over$30 per share!
0 · Reply
winteemelon123
winteemelon123 Sep. 12 at 4:59 AM
$BCDA BioCardia probably the most advanced in study. I think FDA would expedite its review upon pma submission.
1 · Reply
winteemelon123
winteemelon123 Sep. 12 at 4:58 AM
$BCDA A significant advantage over Reheart is CardiAMP does not need invasive open heart surgery as protocol. Many of the targetted patient population probably would be wise to avoud open heart surgery if possible.
0 · Reply
winteemelon123
winteemelon123 Sep. 11 at 10:08 PM
$BCDA
0 · Reply
winteemelon123
winteemelon123 Sep. 11 at 9:14 PM
$BCDA multi billion dollars in market potential with initial commercialisation expected next year upon expected approvals yet little buying and selling.
0 · Reply
winteemelon123
winteemelon123 Sep. 11 at 8:03 AM
$BCDA
0 · Reply
winteemelon123
winteemelon123 Sep. 11 at 7:02 AM
$BCDA imo they could file for PMA next year and need not wait for study completion.
0 · Reply
winteemelon123
winteemelon123 Sep. 11 at 7:01 AM
$BCDA Helix is a pipeline in a product.
1 · Reply
Whateverbro
Whateverbro Sep. 10 at 10:16 PM
$BCDA they filed an 8-k today. about the event in New York. also they still on time for Q3 PREsubmison for the Helix follow-on-de-Nova pre-submission.
1 · Reply
Wizee13
Wizee13 Sep. 10 at 4:39 PM
$BCDA I love how people are talking about fundamentals here, not just chart :)
0 · Reply
Merlintrader
Merlintrader Sep. 10 at 4:28 PM
Elaborato per 10s BioCardia ($BCDA) Stock Hub: Can Helix and Japan Advance Within the Funding Window? — Updated Sep 10 https://www.merlintrader.com/biocardia-bcda-stock-hub/
1 · Reply
winteemelon123
winteemelon123 Sep. 10 at 2:14 PM
$BCDA could be one of those stocks that goes from one dollar to $40 like ROIV did from three dollar plus.
1 · Reply
winteemelon123
winteemelon123 Sep. 9 at 3:10 PM
$BCDA won't be surprised if sp actually goes up upon an impending fund raise. Helix is so close to approval, and same applies to the cell tgerapy in Japan. Partnership and buyout might be anticipated.
0 · Reply
chris_stocks
chris_stocks Sep. 8 at 7:25 PM
$BCDA up, up, up. Can only go up from here.
0 · Reply
DipBuyInvester
DipBuyInvester Sep. 8 at 10:49 AM
$BCDA Catch this dip before it takes off.
0 · Reply
winteemelon123
winteemelon123 Sep. 5 at 7:39 PM
$BCDA competition? Yet it shows cell therapy can work on the heart.
2 · Reply
winteemelon123
winteemelon123 Sep. 5 at 4:21 PM
$BCDA they should be reaching full enrolment soon for their CardiAMP Heart Failure II Trial. Started in early 2024 and targetted 2 years to reach full enrolment.
0 · Reply
winteemelon123
winteemelon123 Sep. 5 at 3:37 PM
$BCDA this news came out after hours. Wonder what that means for cell therapies like what BioCardia is doing clinical for?
1 · Reply
winteemelon123
winteemelon123 Sep. 5 at 11:14 AM
$BCDA life changing therapy
0 · Reply
DipBuyInvester
DipBuyInvester Sep. 4 at 5:25 PM
$BCDA Catch every dip before it takes off.
0 · Reply
winteemelon123
winteemelon123 Sep. 4 at 2:13 PM
$BCDA interesting
1 · Reply
winteemelon123
winteemelon123 Sep. 4 at 10:52 AM
$BCDA Helix and the cell therapy have come a long way.
0 · Reply